[go: up one dir, main page]

YU16399A - ) UPOTREBA INHIBITOR H +, K+ - ATP- aze I FARMACEUTSKA FORMULACIJA ZA SIMULTANU, SEPARATNU ILI SEKVENCIJALNU UPOTREBU, KOJA SADRZI INHIBITOR H +, K+-ATP- aze I GLUKOKORTIKOID INHIBITOR H +, K+- ATP- aze - Google Patents

) UPOTREBA INHIBITOR H +, K+ - ATP- aze I FARMACEUTSKA FORMULACIJA ZA SIMULTANU, SEPARATNU ILI SEKVENCIJALNU UPOTREBU, KOJA SADRZI INHIBITOR H +, K+-ATP- aze I GLUKOKORTIKOID INHIBITOR H +, K+- ATP- aze

Info

Publication number
YU16399A
YU16399A YU16399A YU16399A YU16399A YU 16399 A YU16399 A YU 16399A YU 16399 A YU16399 A YU 16399A YU 16399 A YU16399 A YU 16399A YU 16399 A YU16399 A YU 16399A
Authority
YU
Yugoslavia
Prior art keywords
application
simultaneous
separate
pharmaceutical formulation
glycocorticoid
Prior art date
Application number
YU16399A
Other languages
English (en)
Inventor
Per Lindberg
Jon Pinaso-Masso
Jordi Serra-Carreras
Jan Trofast
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of YU16399A publication Critical patent/YU16399A/sh
Publication of RS49599B publication Critical patent/RS49599B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

Pronalazak daje postupak upotrebe inhibitora H+, K+-ATP-aze i farmaceutske formulacije, opciono sa glukokortikoidom, za lečenje polipoze. Ovaj pronalazak daje upotrebu inhibitora H+, K+-ATP-aze i farmaceutske formulacije za simultano, separatno ili sekvencijalno lečenje Widal-ovog sindroma i astme.
YUP-163/99A 1996-10-11 1997-10-01 Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija RS49599B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9603725A SE9603725D0 (sv) 1996-10-11 1996-10-11 New teatment

Publications (2)

Publication Number Publication Date
YU16399A true YU16399A (sh) 2000-03-21
RS49599B RS49599B (sr) 2007-06-04

Family

ID=20404214

Country Status (33)

Country Link
EP (1) EP0946175B1 (sh)
JP (1) JP4100713B2 (sh)
KR (1) KR100510812B1 (sh)
CN (1) CN1146416C (sh)
AR (1) AR008886A1 (sh)
AT (1) ATE230597T1 (sh)
AU (1) AU738310B2 (sh)
BR (1) BR9711896A (sh)
CA (1) CA2268305C (sh)
CZ (1) CZ298799B6 (sh)
DE (1) DE69718347T2 (sh)
DK (1) DK0946175T3 (sh)
EE (1) EE04043B1 (sh)
ES (1) ES2188995T3 (sh)
HU (1) HUP0000036A3 (sh)
ID (1) ID23692A (sh)
IL (1) IL129324A0 (sh)
IS (1) IS1930B (sh)
MY (1) MY117918A (sh)
NO (1) NO321007B1 (sh)
NZ (1) NZ334786A (sh)
PL (1) PL190902B1 (sh)
PT (1) PT946175E (sh)
RS (1) RS49599B (sh)
RU (1) RU2197966C2 (sh)
SA (1) SA97180641B1 (sh)
SE (1) SE9603725D0 (sh)
SK (1) SK284252B6 (sh)
TR (1) TR199900770T2 (sh)
TW (1) TW568784B (sh)
UA (1) UA59374C2 (sh)
WO (1) WO1998016228A1 (sh)
ZA (1) ZA978842B (sh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
AU760766B2 (en) 1998-08-18 2003-05-22 Regents Of The University Of California, The Preventing airway mucus production by administration of EGF-R antagonists
US7354894B2 (en) 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US6846799B1 (en) * 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
BR0008650B1 (pt) * 1999-03-03 2010-12-28 dispositivo de transmissão via nasal.
EP1453493A2 (en) * 2001-11-19 2004-09-08 ALTANA Pharma AG Reversible proton pump inhibitors for the treatment of airway disorders
WO2003075926A1 (en) * 2002-03-14 2003-09-18 Altana Pharma Ag Use of proton pump inhibitors for the treatment of airway disorders
HRP20041160A2 (en) * 2002-05-07 2005-08-31 Altana Pharma Ag Novel combination for the treatment of airway disorders
NZ536918A (en) * 2002-05-07 2006-09-29 Altana Pharma Ag Combination of pantoprazole and a respiratory agent for the treatment of respiratory diseases
FR2845915B1 (fr) * 2002-10-21 2006-06-23 Negma Gild Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien
WO2004052374A1 (en) 2002-12-12 2004-06-24 Altana Pharma Ag Combination medicament
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
PL1670482T5 (pl) 2003-09-16 2022-10-03 Covis Pharma Gmbh Zastosowanie cyklezonidu w leczeniu chorób układu oddechowego
RU2252025C1 (ru) * 2003-11-28 2005-05-20 Дальневосточный государственный медицинский университет Способ лечения избыточной грануляционной ткани гортани и трахеи
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CN104408249B (zh) * 2014-11-24 2017-09-26 广州供电局有限公司 单芯电缆导体热性参数的确定方法及系统
KR101974504B1 (ko) * 2017-04-10 2019-05-03 재단법인 아산사회복지재단 호산구성 비용종 동물모델

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1429184A (en) * 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
GB1571629A (en) * 1977-11-30 1980-07-16 Fisons Ltd Pharmaceutical compositions containing beclomethasone dipropionate

Also Published As

Publication number Publication date
IS5021A (is) 1999-04-08
AU738310B2 (en) 2001-09-13
IL129324A0 (en) 2000-02-17
PL332692A1 (en) 1999-09-27
TR199900770T2 (xx) 1999-06-21
HUP0000036A3 (en) 2003-02-28
HUP0000036A2 (hu) 2002-05-29
HK1022848A1 (en) 2000-08-25
WO1998016228A1 (en) 1998-04-23
CA2268305A1 (en) 1998-04-23
BR9711896A (pt) 1999-08-24
RS49599B (sr) 2007-06-04
NO991619L (no) 1999-04-06
AR008886A1 (es) 2000-02-23
SE9603725D0 (sv) 1996-10-11
CZ122999A3 (cs) 1999-09-15
RU2197966C2 (ru) 2003-02-10
CN1232397A (zh) 1999-10-20
CN1146416C (zh) 2004-04-21
AU4640997A (en) 1998-05-11
HU0000036D0 (sh) 2002-05-29
NZ334786A (en) 2000-12-22
UA59374C2 (uk) 2003-09-15
ES2188995T3 (es) 2003-07-01
ID23692A (id) 2000-05-11
JP2001508034A (ja) 2001-06-19
ZA978842B (en) 1998-04-14
DK0946175T3 (da) 2003-03-17
ATE230597T1 (de) 2003-01-15
TW568784B (en) 2004-01-01
SK284252B6 (sk) 2004-12-01
PL190902B1 (pl) 2006-02-28
DE69718347D1 (de) 2003-02-13
IS1930B (is) 2004-05-18
SA97180641B1 (ar) 2005-12-18
KR100510812B1 (ko) 2005-08-31
NO991619D0 (no) 1999-04-06
EE9900118A (et) 1999-10-15
SK38499A3 (en) 2000-03-13
CA2268305C (en) 2006-11-28
KR20000049046A (ko) 2000-07-25
MY117918A (en) 2004-08-30
DE69718347T2 (de) 2003-08-28
NO321007B1 (no) 2006-02-27
JP4100713B2 (ja) 2008-06-11
EE04043B1 (et) 2003-06-16
PT946175E (pt) 2003-04-30
EP0946175B1 (en) 2003-01-08
EP0946175A1 (en) 1999-10-06
CZ298799B6 (cs) 2008-02-06

Similar Documents

Publication Publication Date Title
YU16399A (sh) ) UPOTREBA INHIBITOR H +, K+ - ATP- aze I FARMACEUTSKA FORMULACIJA ZA SIMULTANU, SEPARATNU ILI SEKVENCIJALNU UPOTREBU, KOJA SADRZI INHIBITOR H +, K+-ATP- aze I GLUKOKORTIKOID INHIBITOR H +, K+- ATP- aze
BG98902A (bg) Имидазолови производни и тяхната употреба като инхибитори на цитокин
ITMI942025A0 (it) Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia
SE9704186D0 (sv) New composition of matter
NO20061736L (no) Krystallform av epotilon B
EP1028715A4 (en) FORMULATION FOR NASAL SUPPORT AND METHOD OF USE THEREOF
ES2133807T3 (es) Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteasas.
CY1107512T1 (el) Νεες υποκατεστημενες με βενζιμιδαζολιο μορφες δοσολογιας και μεθοδος για τη χρηση τους
NO20012774D0 (no) Preparat og metode hvor det gjöres bruk av eteriske planteoljer
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
BR0010220A (pt) Compostos de pirimidinona
ATE231872T1 (de) Thiazolopyrimidinderivate
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
HUP9901794A2 (hu) Protonpumpa inhibitorok új beadási formája
MXPA04004372A (es) Derivados heterociclicos de glicinamida y su uso medico.
ATE234359T1 (de) Fusionsproteine bestehend aus gewebefaktor- kunitzdomäne als inhibitoren des faktors viia
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
DK0773782T3 (da) Terpenderivater (sarcodictyiner) anvendelse som antitumormidler
HUT77868A (hu) Imidazopiridin-azolidinonok, ezeket tartalmazó gyógyszerkészítmények, alkalmazásuk és eljárás előállításukra
DE69930844D1 (de) Inhibitoren von mycobakterien
WO2001016355A3 (de) In-vitro-testsystem für gamma-sekretase aus angereicherten-membranen
AU2576901A (en) Agents and methods for the treatment of proliferative diseases
IT1289154B1 (it) Derivati di isoflavone loro preparazione e loro impiego terapeutico